Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Policy
November 18, 2021 02:45 PM

Five FDA policy themes to watch for under new leadership

Maya Goldman
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Robert Califf
    Dr. Robert Califf

    Dr. Robert Califf was nominated by President Joe Biden last week to lead the Food and Drug Administration. If confirmed, Califf will lead an agency still fighting against the COVID-19 pandemic while working to innovate.

    Califf previously served as FDA commissioner for nearly a year at the end of the Obama administration. He knows how the agency works and can hit the ground running, stakeholders say. Califf's leadership style revolves around setting key priorities and following through on them, according to Howard Sklamberg, a partner at Arnold & Porter who worked as a deputy commissioner at the FDA during Califf's first tenure.

    Here are five policy themes to watch for as the FDA moves into a new phase of leadership.

    1. Continued attention to COVID-19

    Califf will likely prioritize dealing with the COVID-19 public health emergency, the FDA's constant priority for nearly two years. The agency needs to keep paying attention to vaccine, testing and drug development related to COVID-19, said Heather Pierce, senior director of science policy and regulatory counsel at the Association of Academic Medical Colleges.

    New COVID-19 therapies are still being developed, like Pfizer's pill put up for FDA authorization earlier this week. Califf will likely be involved in those decisions, said Susan Lee, a partner in Goodwin Proctor's life sciences practice.

    Some stakeholders want the FDA to improve the way it communicates pandemic-related policies to providers and patients. Mark Howell, senior associate director for hospital standards and drug policy at the American Hospital Association, said the group has talked with the FDA about streamlining communication around emergency use authorizations and thinks the agency is trying to move towards that.

    2. Transitioning out of EUAs as the pandemic winds down

    The FDA has used EUAs to bring several devices and drugs to market during the pandemic, which have been immensely helpful to hospitals, Howell said.

    But these approvals expire with the public health emergency. The FDA needs to create a transition period so hospitals aren't suddenly left with unauthorized products when those EUAs lapse, Howell said.

    The agency has also exercised enforcement discretion over premarket approval requirements for different products, and it will have to figure out what and how to phase out some of these temporary policies.

    3. Additional focus on—and innovation in—clinical trials

    Califf, considered an expert on clinical trial research, is passionate about improving clinical trials and evidence development, Sklamberg said. Califf will likely make the trial process more open to real-world evidence.

    The pandemic forced the FDA to allow flexibility and innovative clinical trial design, especially around remote monitoring, Lee said. She expects Califf to continue this push.

    Clinical trial innovation could also benefit patients and practitioners by getting therapies on the market sooner.

    4. More FDA policies to reign in drug costs

    The FDA isn't responsible for drug price regulation. But Califf has spoken out against unsustainable drug costs, indicating he could direct the agency to be more proactive about reeling in prices.

    Lee said enthusiasm around innovative clinical trial designs could lead to lower drug costs down the line, since high costs of drug development contribute to high prices for consumers.

    The FDA can also work to enhance competition in the pharmaceutical market as a way to control costs. Sklamberg expects Califf to make sure first and second-generation generic drugs on the market have the right resources. Califf will likely also continue former FDA Commissioner Scott Gottlieb's push to refer anti-competitive behavior in the industry to the Federal Trade Commission, he said.

    AHA hopes to see the FDA continue its work around biosimilars—drugs that are nearly identical to an original pharmaceutical—and interchangeable products under Califf, Howell said.

    "We're all about if you can get more generics to market, especially when we're looking at high-cost biologics," he said.

    5. Pressure to fight opioid and substance use disorder epidemic

    Opioid and substance use disorder continues to devastate America, with overdoses rising during the coronavirus pandemic. The Centers for Disease Control and Prevention announced this week that for the first time, drug overdoses exceeded 100,000 over a 12-month period ending in April 2021.

    Califf dealt with the same crisis as FDA commissioner in 2016 and 2017 and as deputy commissioner for medical products and tobacco before that. The agency began requiring its strongest warning label on opioid packaging under Califf.

    But some lawmakers and advocates think Califf's ties to the pharmaceutical industry make him a poor choice for commissioner. Califf's financial disclosures have reportedly shown consulting fees or money to support his Duke University salary from pharmaceutical companies, including some that manufacture opioids. Four senators opposed Califf's nomination in 2016, and Sen. Joe Manchin (D-W.V.) has already said he won't vote to confirm Califf this time around either.

    These factors could conspire to create additional pressure on and energy from the agency to tackle the epidemic.

    AAMC hopes the FDA can parlay lessons learned from the pandemic into tackling the opioid crisis, Pierce said.

    "We will be looking to the FDA to be partners on addressing the opioid epidemic, and continuing to—really continuing the themes that we hear about through COVID, of public trust, of community engagement, critical issues related to health equity and how the data that go to the FDA can impact what comes out," she said.

    Related Article
    Biden picks former FDA chief Califf to again lead the agency
    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Biden signs organ transplant overhaul measure
    Biden signs organ transplant overhaul measure
    HHS agency
    HHS proposes new protections for people with disabilities
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing